Abstract
Background: G protein coupled receptor 120 (GPR120) is a class of receptors in the gastrointestinal tract (GIT) that is implicated in nutrient sensing and body weight regulation. Functions of GPR120 are thought to be mediated by the release of a group of hormones known as incretins, such as glucagon like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP).
Methods: We have searched PubMed with the keywords "GPR120","GLP-1" and "obesity". Relevant studies were retrieved and included in the review.
Results: Recently, many exogenous compounds have been investigated in their role in the release of GLP-1 and in causing weight loss in obese rats. However, some results question the putative role of GPR120 in metabolic homeostasis.
Conclusion: Herein, we evaluate the potential use of GPR120 as a target receptor in obesity and found it to be ubiquitous throughout the GIT, with various functions in each site. In order to find the optimal drug, the role of GPR120 in each site needs to be defined and selectivity of the potential drug needs to be studied to ensure the success of this growing line of obesity management.
Keywords: Fecal microbiota, GLP-1, GPR120, obesity, treatment.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:GPR 120: The Potential Target for Obesity Treatment
Volume: 16 Issue: 1
Author(s): Peter A. Tanagho and Kyrillus S. Shohdy
Affiliation:
Keywords: Fecal microbiota, GLP-1, GPR120, obesity, treatment.
Abstract: Background: G protein coupled receptor 120 (GPR120) is a class of receptors in the gastrointestinal tract (GIT) that is implicated in nutrient sensing and body weight regulation. Functions of GPR120 are thought to be mediated by the release of a group of hormones known as incretins, such as glucagon like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP).
Methods: We have searched PubMed with the keywords "GPR120","GLP-1" and "obesity". Relevant studies were retrieved and included in the review.
Results: Recently, many exogenous compounds have been investigated in their role in the release of GLP-1 and in causing weight loss in obese rats. However, some results question the putative role of GPR120 in metabolic homeostasis.
Conclusion: Herein, we evaluate the potential use of GPR120 as a target receptor in obesity and found it to be ubiquitous throughout the GIT, with various functions in each site. In order to find the optimal drug, the role of GPR120 in each site needs to be defined and selectivity of the potential drug needs to be studied to ensure the success of this growing line of obesity management.
Export Options
About this article
Cite this article as:
A. Tanagho Peter and S. Shohdy Kyrillus, GPR 120: The Potential Target for Obesity Treatment, Endocrine, Metabolic & Immune Disorders - Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1871530316666151123115611
DOI https://dx.doi.org/10.2174/1871530316666151123115611 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Computer Science in Molecular Medicine: Enabling High- Throughput Research
Current Topics in Medicinal Chemistry Clinical Advances in Bone Regeneration
Current Stem Cell Research & Therapy PREFACE: “The Lower the Better” Association between White-coat Effect-excluded Blood Pressure and Cardiovascular Events in High-risk Hypertension: Insights from SPRINT
Current Hypertension Reviews Cardiovascular Risk Factors and Dietary Patterns
Current Nutrition & Food Science The Genetics and Genomics of Systemic Sclerosis: An Update and Review
Current Rheumatology Reviews Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Patents on Flavonoids
Recent Patents on Biotechnology Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease
Cardiovascular & Hematological Disorders-Drug Targets Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches
Current Pharmaceutical Design Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Review of Diabetic Polyneuropathy: Pathogenesis, Diagnosis and Management According to the Consensus of Egyptian Experts
Current Diabetes Reviews Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Insights into Amyloid Fibril Formation from Mass Spectrometry
Protein & Peptide Letters Direct Vascular Targets For Atherosclerosis Prevention
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Ageing and Nutritional Therapy Adherence in Type 2 Diabetes
Current Diabetes Reviews Managing Sleep Disturbance in Bipolar Disorder
Current Psychiatry Reviews Genetics and Vaccines in the Era of Personalized Medicine
Current Genomics Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics